Prestige Consumer Healthcare (PBH) has drawn investor attention after its latest quarterly results showed lower sales and net income versus the prior year, along with a slightly narrowed full year revenue outlook.

Those earnings and the slightly tighter revenue outlook come after a solid 90 day share price return of 13.24% and a 5 year total shareholder return of 61.60%, set against a weaker 1 year total shareholder return decline of 22.34%. This indicates that longer term holders have still seen gains, even as recent momentum appears more cautious.

If this update has you thinking about how other healthcare names are priced and moving, it could be a good moment to scan a fresh set of 25 healthcare AI stocks as potential watchlist candidates.

With earnings under pressure, guidance nudged lower and the shares trading below some valuation estimates, the real question is whether Prestige Consumer Healthcare now sits at a discount or if the market already sees its future growth coming.

Most Popular Narrative: 13.6% Undervalued

Prestige Consumer Healthcare's most followed valuation narrative puts fair value at about $77.33 per share, above the last close of $66.79. It anchors that view on modest growth and steady profitability assumptions rather than aggressive forecasts.

The company is well positioned to capture long-term growth from increased consumer focus on self-care and preventive health, as evidenced by strong underlying consumption trends, particularly in women's health (Summer's Eve) and international markets, implying sustained core brand revenue resilience and expansion.

Curious what kind of revenue glide path and margin profile are baked into that fair value? The narrative leans on measured growth, small efficiency gains, and a future earnings multiple that assumes investors continue to assign a premium valuation to this cash generator. If you want to see exactly how those moving parts add up to that price, the full story lays it out line by line.

Result: Fair Value of $77.33 (UNDERVALUED)

However, there are real watchpoints here, including ongoing supply constraints around key brands and the risk that heavier e commerce competition chips away at pricing power over time.

Build Your Own Prestige Consumer Healthcare Narrative

If you are not fully sold on this story or prefer to test your own assumptions against the numbers, you can create a custom view in just a few minutes by starting with Do it your way.

A great starting point for your Prestige Consumer Healthcare research is our analysis highlighting 2 key rewards and 1 important warning sign that could impact your investment decision.

Ready to Hunt for Your Next Idea?

If Prestige Consumer Healthcare has you thinking about position sizing and diversification, do not stop here. Line up a few fresh, high conviction watchlist candidates.

• Target resilience in tougher markets by scanning 84 resilient stocks with low risk scores that score well on core risk checks and may help steady your overall returns.
• Focus on quality at a fair price by reviewing 53 high quality undervalued stocks that pair solid fundamentals with valuations some investors might consider appealing.
• Build a shortlist of potential future standouts by checking our screener containing 23 high quality undiscovered gems that many portfolios may not yet hold.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.